The available data concerning the latter topic is still speculative and preliminary, but some authors suggest that it could open a new scenario in the development of selective drugs targeting NRP1, TMPRSS2, or ACE2 in the treatment of RCC. The gene discussed is TMPRSS2; the disease is renal cell adenocarcinoma.